A prospective, multicenter study found that a blood-based miRNA assay combined with CA19-9 improved early detection of pancreatic ductal adenocarcinoma.
|Articles|December 1, 1995
Oncology NEWS International
- Oncology NEWS International Vol 4 No 12
- Volume 4
- Issue 12
Rhône-Poulenc Rorer Acquires Applied Immune Sciences
COLLEGEVILLE, PA--Rhône-Poulenc Rorer Inc. and Applied Immune Sciences, Inc. (AIS) have entered into a definitive agreement and plan of merger providing for the acquisition by Rhône-Poulenc Rorer (through its subsidiary RPR Gencell) of AIS at a price of approximately $7.2 million.
Advertisement
COLLEGEVILLE, PA--Rhône-Poulenc Rorer Inc. and Applied ImmuneSciences, Inc. (AIS) have entered into a definitive agreementand plan of merger providing for the acquisition by Rhône-PoulencRorer (through its subsidiary RPR Gencell) of AIS at a price ofapproximately $7.2 million.
AIS is a leader in cell therapy. At the heart of AIS' technologyis a patented device, the AIS CELLector, that isolates specificpopulations of a patient's cells from blood, bone marrow, or tissuesamples, The cells may then be activated and numerically expandedprior to reinfusion.
The AIS research facility in Santa Clara, Calif, will become theprimary US operating headquarters for RPR Gencell with a focuson the development of ex vivo gene and cell therapy approaches,said Thierry Soursac, MD, PhD, senior vice president, RPR, andgeneral manager, RPR Gencell.
Articles in this issue
almost 31 years ago
Confusion Abounds Over Breast Cancer Risk Factorsalmost 31 years ago
Mislocation of BRCA1 Gene Linked to Nonfamilial Breast Canceralmost 31 years ago
Regular Aspirin Use May Lower Breast Cancer Riskalmost 31 years ago
Study Probes How Aspirin Decreases Prostaglandin Levelsalmost 31 years ago
Scholarships Offered For Palliative Carealmost 31 years ago
National Breast Cancer Month Spotlights Awareness Effortsalmost 31 years ago
Long-term Aspirin Use Reduces Colon Cancer Risk, Study Showsalmost 31 years ago
Panel Recommends FDA Approval of First Protease Inhibitoralmost 31 years ago
FDA Improves Drug Approval Timesalmost 31 years ago
New Strategies Needed to Boost Clinical Trial AccrualsAdvertisement
Related to this article
Final 5-year IMCgp100-202 data show tebentafusp improved OS vs investigator’s choice in untreated HLA-A*02:01–positive metastatic uveal melanoma.
The FDA granted platform technology designation to the immunotherapeutic platform for use in HPV-positive cancers such as head and neck, cervical, and anal.
An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.
Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.
The updated NCCN Guidelines for myeloproliferative neoplasms recommend rusfertide as a category 1 option across both low- and high-risk polycythemia vera.
As part of the ANDA pathway, Bravnetsa is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product, Lutathera.
Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
COA Warns That Price Negotiation for Medicare Part B Drugs Threatens Community Oncology
3
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
4
Using Intrathecal Dendritic Cells for Leptomeningeal Disease From Breast Cancer
5